|1.||Taylor, Bradley K: 2 articles (09/2007 - 04/2002)|
|2.||Yalamuri, Suraj M: 1 article (01/2013)|
|3.||Spofford, Christina M: 1 article (01/2013)|
|4.||Brennan, Timothy J: 1 article (01/2013)|
|5.||Herzog, Herbert: 1 article (07/2012)|
|6.||Sainsbury, Amanda: 1 article (07/2012)|
|7.||Lamghari, Meriem: 1 article (07/2012)|
|8.||Zhang, Lei: 1 article (07/2012)|
|9.||Sousa, Daniela M: 1 article (07/2012)|
|10.||Enriquez, Ronaldo F: 1 article (07/2012)|
12/01/2003 - "In addition, hyperphagia was partially reversed by intracerebroventricular administration of the NPY Y1 receptor antagonist BIBO3304. "
10/01/1998 - "3. 30 microg BIBO 3304 administered into the paraventricular nucleus inhibited the feeding response induced by 1 microg NPY as well as the hyperphagia induced by a 24 h fast implying a role for Y1 receptors in NPY mediated feeding. "
08/15/2004 - "The selective Y1 receptor antagonist BIBO 3304 blocked the NPY- and Y1-receptor agonist-induced suppression of conditioned tachycardia without affecting basal HR. The tachycardia elicited by both conditioned and unconditioned stressor was effectively attenuated by the Y1 receptor agonist. "
10/01/2011 - "However, unlike in the feeding test, BIBO 3304 did not attenuate the NPY-induced anxiolysis in the shock-probe test. "
10/01/2011 - "This anxiolysis was attenuated by co-infusion with BIBO 3304 (0.30 μg) in Experiment 2. Lastly, rats infused with NPY showed decreases in the duration of burying behavior in the shock-probe burying test, also indicative of anxiety reduction. "
01/05/2013 - "Pain-related behaviors were tested after incision in rats treated with intrathecal NPY, Y(1) receptor antagonist (BIBO3304--Chemical Name: N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]butyl]-α-phenyl-benzeneacetamide ditrifluoroacetate), Y(2) receptor antagonist (BIIE0246--Chemical Name: N-[(1S)-4-[(Aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-oxoethyl]-cyclopentaneacetamide), combined NPY+antagonists, morphine, or vehicle. "
|3.||Morphine (MS Contin)
|6.||neuropeptide Y (13-36)